Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects-Reference-Cited by-同舟云学术

Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects

Published:2003-11 Issue:2 Volume:69 Page:155-160
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Bremer Michael,Klöpper Karin,Yamini Paria,Bendix-Waltes Regina,Dörk Thilo,Karstens Johann H.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference33 articles.

1. Does variability in normal tissue reactions after radiotherapy have a genetic basis—where and how to look for it?;Andreassen;Radiother Oncol,2002

2. Molecular genotyping shows that ataxia–telangiectasia heterozygotes are predisposed to breast cancer;Athma;Cancer Genet Cytogenet,1996

3. IVS10-6TG, an ancient ATM germline mutation linked with breast cancer;Broeks;Hum Mutat,2003

4. Dominant negative ATM mutations in breast cancer families;Chenevix-Trench;J Natl Cancer Inst,2002

5. Common Toxicity Criteria Version 2.0. CTEP website: http://ctep.info.nih.gov/reporting/ctc.html.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia–Telangiectasia Mutated Variant Carriers;Cancers;2024-04-05

2. Breast Irradiation Is Well Tolerated in Carriers of a Pathogenic ATM Variant;Practical Radiation Oncology;2024-01

3. Moving the Needle Forward in Genomically-Guided Precision Radiation Treatment;Cancers;2023-11-07

4. A systematic review exploring the role of modern radiation for the treatment of Hereditary or Familial Breast Cancer;Radiotherapy and Oncology;2022-11

5. Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers;Current Opinion in Oncology;2022-09-27